Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calcipotriol + nicotinamide
- Development stage
- Unknown
- Lead developer
- NextGen Biomed
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
A topical combination therapy consisting of calcipotriol (a synthetic vitamin D3 analog) and nicotinamide (a vitamin B derivative) used primarily for the treatment of plaque psoriasis. The combination demonstrates synergistic effects in reducing symptoms of hyperproliferative skin diseases, with calcipotriol affecting cell differentiation through vitamin D receptors while nicotinamide inhibits proinflammatory cytokines and reduces keratinocyte proliferation.
- Other names
- calcipotriene + nicotinamide
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on calcipotriol + nicotinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calcipotriol + nicotinamide.